Immutep And Cardiff University Sign Exclusive License For Next Generation Anti-LAG-3 Molecules For Cancer
Portfolio Pulse from Benzinga Newsdesk
Immutep Limited has signed an exclusive license agreement with Cardiff University to develop and commercialize next-generation anti-LAG-3 molecules for cancer treatment. This collaboration has identified promising compounds that block LAG-3, an immune checkpoint that reduces the immune system's response to fight cancer.
June 25, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep Limited has entered into an exclusive license agreement with Cardiff University to develop and commercialize anti-LAG-3 molecules for cancer treatment. This partnership has identified promising compounds that could enhance the company's pipeline and market position.
The exclusive license agreement with Cardiff University provides Immutep with promising new compounds to develop and commercialize, potentially enhancing its product pipeline and market position. This positive development is likely to boost investor confidence and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100